

Enamine Provides Exquiron with Large Novel Diverse Screening Compound Library

KIEV, Ukraine and BASEL, Switzerland, June 3rd 2013 – Enamine Ltd, a leading provider of screening compounds, chemical building blocks and discovery services, and Exquiron Biotech AG, a company specializing in early stage drug discovery services, today announced a multiyear collaboration under which Enamine will provide a carefully selected, novel diverse screening compound library. This library will be made available by Exquiron to screening clients for hit discovery projects.

The library provided by Enamine is a great asset for discovery programs as it includes a high number of diverse drug-like compounds. Exquiron and its clients will also have access to Enamine's full range of chemistry expertise, for post screening follow-up.

Dr. Serge Parel, VP Chemistry and Research Informatics, Exquiron, commented: "Offering high quality chemistry to our clients is crucial. We are impressed by the quality and novelty of Enamine's compounds, coupled with their logistics and support services. Together we can offer clients excellent value."

"We are pleased that Exquiron has chosen to work with us. We see this as confirmation of the quality of our chemistry and services, and hope that our collaboration will contribute to Exquiron's success," added Michael Bossert, Head of Strategic Alliances, Enamine.

ENDS

About Exquiron

Exquiron is a newly formed Swiss company with service offerings in early stage drug discovery. Services span from development of hit identification and profiling assays to compound selection, high throughput screening, hit profiling and characterization, and SAR expansion. The Exquiron team brings extensive skills and know-how in all areas of hit discovery, including target class coverage, applicable technologies, data evaluation and reporting, and project management.

www.exquiron.com

About Enamine

Established in Kiev in 1991, Enamine is a leading provider of innovative screening libraries, building blocks, fragments, and comprehensive chemistry support in hit discovery and integrated drug discovery services. Enamine's design and synthesis capabilities allow the addition of more than 250,000 new organic compounds to its catalogue each year. Enamine offers collaborative expertise to exclusively design and supply libraries of new, potentially bioactive organic compounds and building blocks. Enamine serves the pharmaceutical, agrochemical, cosmetic, nutritional and petrochemical industries.

www.enamine.net

Contacts:

Media enquiries

Lorna Cuddon
Zyme Communications
E: Lorna.cuddon@zymecommunications.com
T: +44 (0)7811996942

Enamine

Michael Bossert
Head Strategic Alliances
E: m.bossert@enamine.net
T: +38 044 537 32 18

Exquiron

Serge P. Parel
VP Chemistry and Research Informatics
E: sparel@exquiron.com
T: +41 61 716 85 77